We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Generic Pharmaceutical Association (GPhA) issued a study July 31 that shows the long-term effect of allowing brand drug companies to launch an authorized generic during a generic firm's 180-day exclusivity period will be decreased competition and reduced access to cheaper drugs.
Mentholatum announced Aug. 1 that it would conduct a nationwide voluntary recall of its WellPatch Cough & Cold Soothing Vapor Pads due to potential serious adverse health effects that could result if children eat the product.
Genetic test makers marketing their products for direct-to-consumer sale can expect to find themselves under a regulatory microscope after a government report found some manufacturers are testing the limits of advertising claims.
The Generic Pharmaceutical Association (GPhA) issued a study July 31 showing that the long-term effect of allowing brand drug companies to launch an authorized generic during a generic firm's 180-day exclusivity period will be decreased competition and reduced access to cheaper drugs.
Several governors are demanding that the FDA issue guidances for generic versions of insulin and human growth hormone (HGH) in order to drive down drug costs.
Mentholatum announced Aug. 1 that it would conduct a nationwide voluntary recall of its WellPatch Cough & Cold Soothing Vapor Pads due to potential serious adverse health effects that could result if children eat the product.
Using information technology (IT) in chronic disease management systems (CDMSs) and electronic medical records (EMRs) offers new ways to combat disease and cut costs, said a new white paper from the California HealthCare Foundation (CHCF).
Less than two weeks after recalling a single lot of its Ultravist Injection X-ray contrast agent, Berlex announced July 31 the recall of all lots worldwide.